CYP2C9 and CYP2C19 genetic polymorphisms:: frequencies in the south Indian population

被引:82
作者
Jose, R
Chandrasekaran, A [1 ]
Sam, SS
Gerard, N
Chanolean, S
Abraham, BK
Satyanarayanamoorthy, K
Peter, A
Rajagopal, K
机构
[1] Jawaharlal Inst Postgrad Med Educ & Res, Dept Pharmacol, Pharmacogen Lab, Pondicherry, India
[2] Hop Robert Debre, INSERM, U458, F-75019 Paris, France
[3] Mahatma Gandhi Univ, Dept Pharmaceut Sci, Kottayam, Kerala, India
[4] Rangaraya Med Coll, Dept Pharmacol, Kakinada, Andhra Pradesh, India
[5] Univ Agr Sci, GKVK, Dept Biotechnol, Bangalore, Karnataka, India
关键词
allele; CYP2C19; CYP2C9; PCR-RFLP; polymorphism; south India;
D O I
10.1111/j.1472-8206.2004.00307.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of the study was to establish the frequencies of CYP2C9*1, *2, *3 and CYP2C19*1, *2 and *3 in the south Indian population and to compare them with the inter-racial distribution of the CYP2C9 and CYP2C19 genetic polymorphisms. Genotyping analyses of CYP2C9 and CYP2C19 were conducted in unrelated, healthy volunteers from the three south Indian states of Andhra Pradesh, Karnataka and Kerala, by the polymerase chain reaction-restriction fragment-length polymorphism (PCR-RFLP). The allele frequencies of the populations of these three states were then pooled with our previous genotyping data of Tamilians (also in south India), to arrive at the distribution of CYP2C9 and CYP2C19 alleles in the south Indian population. Frequencies of CYP2C9 and CYP2C19 alleles and genotypes among various populations were compared using the two-tailed Fisher's exact test. The frequencies of CYP2C9*1, *2 and *3 in the south Indian population were 0.88 (95% CI 0.85-0.91), 0.04 (95% CI 0.02-0.06) and 0.08 (95% CI 0.06-0.11), respectively. The frequencies of CYP2C9 genotypes *1/*1, *1/*2, *1/*3, *2/*2, *2/*3 and *3/*3 were 0.78 (95% CI 0.74-0.82), 0.05 (95% CI 0.03-0.07), 0.15 (95% CI 0.12-0.18), 0.01 (95% CI 0.0-0.02), 0.01 (95% CI 0.0-0.02) and 0.0, respectively. CYP2C19*1, *2 and *3 frequencies were 0.64 (95% CI 0.60-0.68), 0.35 (95% CI 0.31-0.39) and 0.01 (95% CI 0.0-0.03), respectively. As a result of a significant heterogeneity, the data on CYP2C19 genotype frequencies were not pooled. The frequency of CYP2C9*2 mutant alleles in south Indians was higher than in Chinese and Caucasians, while CYP2C9*3 was similar to Caucasians. CYP2C19*2 was higher than in other major populations reported so far. The relatively high CYP2C19 poor-metabolizer genotype frequency of 12.6% indicates that over 28 million south Indians are poor metabolizers of CYP2C19 substrates.
引用
收藏
页码:101 / 105
页数:5
相关论文
共 15 条
[1]   Allele and genotype frequency of CYP2C9 in Tamilnadu population [J].
Adithan, C ;
Gerard, N ;
Vasu, S ;
Balakrishnan, R ;
Shashindran, CH ;
Krishnamoorthy, R .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (8-9) :707-709
[2]   Allele and genotype frequency of CYP2C19 in a Tamilian population [J].
Adithan, C ;
Gerard, N ;
Vasu, S ;
Rosemary, J ;
Shashindran, CH ;
Krishnamoorthy, R .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (03) :331-333
[3]  
Aynacioglu AS, 1999, BRIT J CLIN PHARMACO, V48, P409
[4]   Association between blood carisoprodol:: meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers:: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects? [J].
Bramness, JG ;
Skurtveit, S ;
Fauske, L ;
Grung, M ;
Molven, A ;
Morland, J ;
Steen, VM .
PHARMACOGENETICS, 2003, 13 (07) :383-388
[5]   Pharmacogenetics of the major polymorphic metabolizing enzymes [J].
Daly, AK .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2003, 17 (01) :27-41
[6]   High and variable frequencies of CYP2C19 mutations:: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands [J].
Kaneko, A ;
Lum, JK ;
Yaviong, J ;
Takahashi, N ;
Ishizaki, T ;
Bertilsson, L ;
Kobayakawa, T ;
Björkman, A .
PHARMACOGENETICS, 1999, 9 (05) :581-590
[7]   CYP2C19 genetic mutations in North Indians [J].
Lamba, JK ;
Dhiman, RK ;
Kohli, KK .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (03) :328-335
[8]   Cytochrome P4502C9 polymorphisms: a comprehensive review of the in-vitro and human data [J].
Lee, CR ;
Goldstein, JA ;
Pieper, JA .
PHARMACOGENETICS, 2002, 12 (03) :251-263
[9]   DNA SEQUENCING WITH CHAIN-TERMINATING INHIBITORS [J].
SANGER, F ;
NICKLEN, S ;
COULSON, AR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1977, 74 (12) :5463-5467
[10]   METABOLIC DISPOSITION OF PROGUANIL IN EXTENSIVE AND POOR METABOLIZERS OF S-MEPHENYTOIN 4'-HYDROXYLATION RECRUITED FROM AN INDONESIAN POPULATION [J].
SETIABUDY, R ;
KUSAKA, M ;
CHIBA, K ;
DARMANSJAH, I ;
ISHIZAKI, T .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 39 (03) :297-303